Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

phase 1 GAZE clinical trial will assess 4D-175 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Next Previous
Search
Trial Profile

phase 1 GAZE clinical trial will assess 4D-175 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 4D 175 (Primary)
  • Indications Atrophy
  • Focus Adverse reactions
  • Acronyms GAZE

    • Most Recent Events

    • 13 Nov 2024 According to 4DMT media release, the enrollment expected to begin in Q1 2025
    • 08 Aug 2024 According to 4DMT media release, the enrollment expected to begin in H2 2024
    • 25 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top